Clinical Trial Detail

NCT ID NCT03294083
Title A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors SillaJen, Inc.
Indications

clear cell renal cell carcinoma

Therapies

Cemiplimab + JX-594

Age Groups: adult senior

No variant requirements are available.